Room-temperature exposure for extended periods may reduce potency by 10-15% per month, depending on light exposure and humidity
not primarily appetite-driven (OUP Academic) Expected weight loss (this is where many people get misled) In major obesity trials: Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed) Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks , dose-dependent (SURMOUNT-1) (PubMed) AOD-9604s best-known human signal is kilograms, not double-digit percentages , and later studies did not sustain a strong obesity-drug profile
Supplementing with this is a very effective treatment for B12 deficiencies commonly found in patients who suffer from diseases or have nutritional deficits (such as ultra low calorie diets)
It is also used for canker sores, cataracts, Alzheimer disease, osteoporosis, fatigue, and many other conditions
The full per-batch Certificate of Analysis is available on request from [email protected]